Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2021-05-31 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于“灵康转债”开始转股的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the start of the conversion period for a convertible bond issued by Lingkang Pharmaceutical Group Co., Ltd. It includes bond code, conversion price, conversion period, bond issuance details, conversion procedures, price adjustment formulas, and related terms. The document is an official notice about the convertible bond conversion process and terms, not a financial report or earnings release. It is not a full annual or interim report, nor a management discussion or audit report. It is a capital/financing update related to convertible bond issuance and conversion terms. The document length is 3659 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-05-31 Chinese
关于“灵康转债”转股价格调整的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the adjustment of the conversion price of its convertible bonds (bond code 113610). It details the previous and adjusted conversion prices, the effective date of the adjustment, and the formula basis for the adjustment, referencing the company's profit distribution plan approved at the 2020 annual shareholders meeting. The document is short (1547 characters) and focuses on a specific capital structure change related to convertible bonds, specifically the adjustment of the conversion price due to dividend distribution. This fits the definition of a Capital/Financing Update (CAP), as it concerns changes in the company's capital structure and financing instruments. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2021-05-24 Chinese
2020年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2020 annual dividend distribution by Lingkang Pharmaceutical Group Co., Ltd. It details the dividend per share, relevant dates for dividend distribution, tax treatment, and contact information. The document is relatively short (2142 characters) and focuses solely on dividend payment details rather than presenting financial statements or comprehensive financial performance. It is not a full annual report or earnings release but a specific notice about dividend distribution. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2021-05-24 Chinese
关于控股股东股票质押式回购交易延期购回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of the repurchase period for a stock pledge transaction by the controlling shareholder. It details the number of shares pledged, the extension of the pledge period, and the risk assessment related to the pledge. There is no financial report, earnings data, or management discussion. The document is a formal disclosure about a capital/financing activity related to stock pledge and repurchase arrangements. It is not a full financial report, audit, or earnings release, but an update on financing arrangements involving share pledges. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on this specific financing update, not a report publication or regulatory filing of a different nature.
2021-05-19 Chinese
股东减持股份计划公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's current holdings, the planned reduction amount, timing, methods, and compliance with relevant regulations. There is no financial data, earnings information, or management discussion. The document is focused on shareholding changes by a shareholder, specifically a reduction in shares held. This fits the category of Major Shareholding Notification, which covers notifications of changes in significant share ownership levels.
2021-05-14 Chinese
2020年年度股东大会法律意见书
Regulatory Filings
2021-05-13 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.